Research
Metabolic adaptation
Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%).
Tirzepatide significantly reduces the risk of developing type 2 diabetes in individuals with obesity and prediabetes.
StrongSupportsmedium confidence
Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).
Why this rating
Based on a large randomized controlled trial.
Source
Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff et al. · New England Journal of Medicine · 2024
rct · n=2539Cited 359×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →